Xarelto is an oral anticoagulant drug owned by Janssen Pharmaceuticals. The drug contains the active ingredient rivaroxaban and it was first authorized for market use on July 1, 2011. Xarelto holds a total of 8 drug patents, none of which have expired so far. Some of the patents for Xarelto include ones with titles such as 'Solid, orally administrable pharmaceutical composition' and 'Substituted oxazolidinones and their use in the field of blood coagulation'.
The last patent for Xarelto is set to expire on July 31, 2039. Therefore, the Xarelto generic version could potentially be available after that date.
Xarelto is utilized for a wide range of health conditions related to blood clots and cardiovascular events. These include the reduction of stroke and systemic embolism risk, treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), prevention of major cardiovascular events in chronic coronary artery disease (CAD) or peripheral artery disease (PAD), and prophylaxis of venous thromboembolism in medical patients at risk for thromboembolic complications not at high risk of bleeding. The drug's active ingredient, rivaroxaban, contributes to its effectiveness by blocking the clotting (blood-thinning) factor Xa, which prevents thrombin formation. This process helps to reduce the formation of blood clots.
Xarelto holds a total of eight patents, with the last one expiring on July 31, 2039. The active drug patents protect the composition and utility of Rivaroxaban. Below is the detailed patent information: